Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Traws Pharma, Inc. - Common Stock (NQ:TRAW)

2.390 -0.180 (-7.00%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Traws Pharma, Inc. - Common Stock

Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
From Traws Pharma, Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Appoints Mark Guerin as Chief Financial Officer
Via Investor Brand Network
Annovis Appoints Mark Guerin as Chief Financial Officer
From Annovis Bio Inc.
Via GlobeNewswire
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Reports Second Quarter 2025 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
From Traws Pharma, Inc.
Via GlobeNewswire
MAG 8 Momentum: NIVF, TRAW, KPRX, PNPN.V Lead $3 Undercard Surge – More Stocks Inside!
Via AB Newswire
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Reports Full Year 2024 Results and Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Announces Management Updates
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human Primates
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma’s Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Provides Business Update and Reports Q3 2024 Financial Results
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
Differentiated resistance profile positions Traws’ program as a potential class leader 
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
From Traws Pharma, Inc.
Via GlobeNewswire
Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
From Traws Pharma, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.